Richard M. Wright - 03 Jun 2024 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SR. VP & CCO
Signature
/s/ Sam Martin, attorney-in-fact for Richard M. Wright
Issuer symbol
CLDX
Transactions as of
03 Jun 2024
Net transactions value
-$311,813
Form type
4
Filing time
05 Jun 2024, 16:05:45 UTC
Previous filing
20 Jun 2023
Next filing
17 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $57,338 +20,625 +9916% $2.78* 20,833 03 Jun 2024 Direct
transaction CLDX Common Stock Options Exercise $797,132 +28,469 +137% $28.00 49,302 03 Jun 2024 Direct
transaction CLDX Common Stock Options Exercise $413,070 +18,375 +37% $22.48 67,677 03 Jun 2024 Direct
transaction CLDX Common Stock Sale $924,658 -27,580 -41% $33.53 40,097 03 Jun 2024 Direct F1
transaction CLDX Common Stock Sale $654,695 -19,264 -48% $33.99 20,833 03 Jun 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (right to buy) Options Exercise $0 -20,625 -100% $0.000000* 0 03 Jun 2024 Common Stock 20,625 $2.78 Direct F3
transaction CLDX Incentive Stock Option (right to buy) Options Exercise $0 -28,469 -68% $0.000000 13,531 03 Jun 2024 Common Stock 28,469 $28.00 Direct F4
transaction CLDX Incentive Stock Option (right to buy) Options Exercise $0 -18,375 -44% $0.000000 23,625 03 Jun 2024 Common Stock 18,375 $22.48 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.81 to $33.81 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.815 to $34.20 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3 As of June 19, 2023, the option is fully vested.
F4 25% vested on June 17, 2022 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
F5 25% vested on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.